Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter Phase 2, Open Label Study of Intratumoral Tavokinogene Telseplasmid (Tavo, pIL-12) + Electroporation With Pembrolizumab in Patients With Stage 3/4 Melanoma Who Are Progressing on Either Pembrolizumab or Nivolumab Treatment

NCT03132675 is registered in ClinicalTrials.gov with OncoSec Medical Incorporated as lead sponsor.

NCT NCT03132675
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03132675 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter Phase 2, Open Label Study of Intratumoral Tavokinogene Telseplasmid (Tavo, pIL-12) + Electroporation With Pembrolizumab in Patients With Stage 3/4 Melanoma Who Are Progressing on Either Pembrolizumab or Nivolumab Treatment
Lead sponsor
OncoSec Medical Incorporated
Phase
Phase 2
Overall status
Unknown status
Start date
October 3, 2017
Completion date
July 31, 2024
Enrollment
143 (estimated)
Sites
33

Conditions

As the registry lists them; a condition with its own page is linked.

stage iii/iv melanoma